PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocad

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biocad Announces New Treatment for Oncological Diseases - New Russian medical preparation Leucostim significantly improves effectiveness and availability in modern treatment of oncological diseases - Leucostim.ru
Biocad Announces New Treatment for Oncological Diseases

 

NewswireToday - /newswire/ - Moscow, Russia, 2006/01/09 - New Russian medical preparation Leucostim significantly improves effectiveness and availability in modern treatment of oncological diseases - Leucostim.ru.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Russian biotech company Biocad has successfully completed a multicenter comparative clinical trial of the first domestic granulocyte colony stimulating factor Leucostim. This trial was performed in three leading Moscow cancer centers. Leucostim was used for the treatment of 80 cancer patients with neutropenia after cytotoxic chemotherapy. 100% efficacy of Leucostim was demonstrated; its effect was profound and stable.

Results of the trial have proved that Leucostim has an excellent safety profile and a remarkable efficacy. Therefore Leucostim can be recommended for clinical use for treatment and prophylaxis of chemotherapy-related neutropenia.
All research that resulted in development of Leucostim was performed by Russian scientists. ZAO Biocad manufactures Leucostim in its ultramodern facility in Moscow region according to GMP regulations.

The launch of Leucostim is expected in mid-2006. Availability of this generic drug will make the effective therapy of cancer more affordable, which is of special importance for pediatric oncology and hematology. Therefore, by introducing this product into the Russian market Biocad contributes to the initiatives of the President of Russian Federation who has recently stipulated in the “Health” National Program that availability of hi-tech medical help has to be a priority.

Introduction of the first domestic granulocyte colony stimulating factor Leucostim into the medical practice now depends on whether governmental regulatory bodies will keep to the usual drug approval schedule.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocad

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biocad Announces New Treatment for Oncological Diseases

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Biocad.ru 
+7 495 9926628
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocad securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocad / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Persistence Market Research (P) Ltd

Visit RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)